394 - A retrospective study of cisplatin/vinorelbine versus capecitabine/vinorelbine as second-line or third-line treatment in advanced breast cancer

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anticancer agents
Breast Cancer
Therapy
Biological therapy
Presenter Yunpeng Liu
Authors Y. Liu1, S. Shi1, X. Qu1, J. Shi2, L. Zhang2, L. Xu2, Y. Teng3
  • 1Medical Oncology, The First Hospital of China Medical University, 110001 - Shenyang/CN
  • 2Department Of Oncology, The First Affiliated Hospital of China Medical University, 110001 - Shenyang/CN
  • 3Oncology Dept., The First Affiliated Hospital of China Medical University, 110001 - Shenyang/CN

Abstract

Purpose

To compare the efficacy and safety of cisplatin or capecitabine, both with vinorelbine, as second-line or third-line treatment in advanced breast cancer previously treated with anthracyclines and/or taxanes.

Methods

From June 2004 to November 2011, 62 advanced breast cancer patients were eligible. Patients (38) enrolled in group NP received VIN 25mg/m2 on day 1 and 8 combined with Cisplatin 75mg/m2 on day 1 of a 21-day cycle. Patients (24) enrolled in group NX received VIN 25mg/m2 on day 1 and 8 of a 21-day cycle combined with CAP 1000mg/m2 twice daily for 14 consecutive days followed by 7 days of rest. Tumor assessment was performed every 2 cycles according to RESIST criteria. Toxicity was assessed according to National Cancer Institute Common Toxicity Criteria (version 3.0).

Results

The overall response rate (ORR) in group NP was 47.4%, all were partial responses (PRs). In group NX, ORR was 33.3% (P = 0.275), with 4.2% CRs and 29.2% PRs. Median time to progression (TTP) was 6.1 months (range, 3.2-9.0 months) in group NP and 6.3 months (range, 4.1-8.5 months) in group NX(P = 0.783). COX regression showed no statistically significant difference (P = 0.782, OR = 0.920). Median overall survival (OS) was 28.8 months (range, 21.6-36.0 months) in group NP and 15.1 months (9.6-20.6 months) in group NX(P = 0.027, OR = 0.495). COX regression showed a statistically significant difference(P = 0.045). Neutropenia was the most frequent hematologic toxicity, with 57.9% grade 3/4 neutropenia observed in group NP and 38.1% in group NX(P = 0.145). 13.2% grade 3/4 vomiting was seen in group NP and no grade 3/4 vomiting in group NX. No grade 3/4 nephrotoxicity or hand-foot syndrome was noted in both groups.

Conclusion

Better OS was seen in group NP than in group NX. Treatment-related toxicity in both groups was manageable.

Disclosure

All authors have declared no conflicts of interest.